SpectraCure AB (DE:2OK)
FRANKFURT:2OK
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€4.71M
Enterprise Value€26.27M
Total Cash (Recent Filing)€13.53M
Total Debt (Recent Filing)€3.01M
Price to Earnings (P/E)―
Beta-84.50
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe company’s low nominal debt relative to equity materially reduces near-term solvency and interest burden risk, giving management flexibility to fund clinical programs or raise capital on more favorable terms. This conservative leverage profile supports resilience over the next 2–6 months.
Integrated Proprietary PlatformThe IDOSE platform's integration of planning, monitoring and light-delivery creates a differentiated product architecture that can improve clinical workflow and outcomes. Such system-level IP and clinical utility are durable advantages for adoption, partnerships, and reimbursement progress over months.
Focused Initial IndicationConcentrating commercialization and clinical development initially on prostate cancer narrows regulatory and payer pathways, enabling targeted trials and clearer comparator endpoints. This focus increases probability of early clinical traction and strategic partnerships within a 2–6 month horizon.
Bears Say
Minimal Revenue / Pre-commercial StatusThe firm remains essentially pre-commercial with negligible revenue, meaning operating costs cannot be absorbed by sales. That structural lack of recurring revenue keeps the company dependent on financing and limits evidence of product-market fit, a persistent risk over the coming months.
Accelerating Cash BurnFree cash flow deterioration and a large negative FCF indicate accelerating cash burn that will materially shape near-term strategy. The trend raises probability of additional financing, potential dilution, or operational trade-offs, creating a structural constraint on executing clinical and commercial plans.
Deepening Net Losses And Eroding EquityRapidly larger net losses alongside a shrinking equity base indicate cumulative cash deficits and prior financings have diluted capital cushions. This erosion reduces financial flexibility and increases reliance on new funding or strategic partnering, a durable risk to execution over the next several months.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €4.71M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.